Conference Update: ASCO and WCGIC 2023
Conference Update: ASCO and WCGIC 2023
An expert perspective on the latest data in precision oncology
An expert perspective on the latest data in precision oncology
Prof. Andrea Sartore-Bianchi
In this clinical update video, Prof. Andrea Sartore-Bianchi shares his perspective on key data from ASCO and the World Conference on Gastrointestinal Cancer (WCGIC), 2023.
He reviews data from:
- DESTINY-PanTumor02 trial in HER2-expressing solid tumours
- KontRASt-01 trial in non-small cell lung cancer (NSCLC)
- ADVL 1823 trial in infantile fibrosarcoma
- A retrospective study on molecular profiling on advanced biliary tract cancers
Prof. Andrea Sartore-Bianchi
Medical Oncologist
Niguarda Cancer Center
Italy
Precision Oncology Update from ASCO and WCGIC 2023
Video | 
5 min
|
Jul 2023
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Clinical Takeaways
-
DESTINY-PanTumour02: Study shows T-DXd to be a potential new treatment option for patients with HER2-expressing solid tumours, with higher efficacy in IHC 3+ and efficacy also in anti-HER2 pre-treated patients
-
KontRASt-01: JDQ443 exhibits potent antitumour activity in NSCLC with good disease control and partial responses, as well as a good tolerability profile
-
ADVL1823: First data in first-line treatment with larotrectinib in the NTRK+ infantile fibrosarcoma population, with data suggesting that local control (surgery) remains important to achieve long-term results
-
Molecular Profiling in Biliary Cancers (BTC): the study highlights the importance of conducting NGS upfront for BTC. Treatment with a matched targeted therapeutic provides benefit in terms of DCR, PFS and OS
Selected abstracts
ASCO 2023
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
- Abstract: LBA3000
- Presenter: Funda Meric-Bernstam, MD
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).
- Abstract: 9007
- Presenter: Philippe Alexandre Cassier MD, PhD
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.
- Abstract: 10008
- Presenter: Theodore Willis Laetsch, MD
WCGIC 2023
SO-4 Impact of molecular profiling on survival in patients with advanced biliary tract cancers.
- Short Oral Presentation Clinical Biliary Tract Cancer, Biomarkers and Translational Research
- Presenter: Leony Anton
This educational programme is supported by an Independent Medical Education Grant from Bayer
PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.
Other programmes of interest
2 min
Other programmes developed by Prof. Andrea Sartore-Bianchi
Prof. Andrea Sartore-Bianchi
Medical Oncologist
Niguarda Cancer Center
Italy
